Skip to main content
. 2021 Apr 22;6(8):e146316. doi: 10.1172/jci.insight.146316

Figure 4. Mapping of SARS-CoV-2 antibody reactivity in sera from uninfected individuals.

Figure 4

Serum antibody binding to 15-mer peptides distributed across the SARS-CoV-2 proteome or an IgG-binding peptide (positive control), from 5 randomly selected prepandemic samples, adults showing high level of spike or RBD reactivity (n = 20 each), or infants (n = 5). Values represent signals on a scale from 0 to 10, after subtracting background. The column labeled C shows the immunoreactivity signal in the absence of sera, but with the addition of anti–human IgA, IgM, and IgG horse-radish peroxidase–coupled secondary antibody. In the spike protein, labels indicate the N-terminal (NTD), C-terminal (CTD), or receptor-binding (RBD) domains, receptor-binding motif (RBM), heptad repeat sequence (HR1), central helix (CH), or connector domain (CD); N, nucleocapsid protein; M, membrane protein; ORF, open-reading frame polypeptide proteins; nsp, nonstructural proteins.